PDCD1 and neoplasm: With the advent of facile gene editing technologies, CRISPR-Cas9 has been used for disruption of the PDCD1 gene encoding for PD1, and this has resulted in the enhancement of anti-tumor effects of CAR-T in animal models [41,42].